HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates | Breast Cancer Research | Full Text

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates | Breast Cancer Research | Full Text

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).

Authors:Alberto Ocaña, Eitan Amir and Atanasio Pandiella

Citation:Breast Cancer Research 2020 22:15

Content type:Review

Published on: 31 January 2020

• ViewFull Text
 
• ViewPDF